Abstract
Objective:Previous studies have shown that biologic agents out of the nine medicines might be beneficial for the treatment of SLE. The aim of this study was to evaluate the most effective medication of six biologic agents in treatment of SLE using network meta-analysis (NMA). The performance of these processes is ranked according to the results of this analysis.Methods:Multiple databases including PubMed, EMBASE and Cochrane Library was used to identify applicable articles and collect relevant data to analyzed by using STATA (13.0) software. The papers included in this study were divided into control group (placebo) and observation group (one of the six medicines).Results:A total of 21 eligible RCTs of biologic agents were identified, a total of 995 papers were included, and the results showed that the belimumab had the highest probability of being the most clinically efficacious intervention, with a surface under the cumulative ranking (SUCRA) curve of 75.0, was significantly superior (P < 0.05) to placebo alone. The blisibimod was the worst, with a SUCRA value of 29.4. The other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) were insignificantly superior (P > 0.05) to placebo alone.Conclusions:Belimumab had the highest probability of being the best treatment for SLE compared with the other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab). The other biologic agents indicated an insignificant difference in efficacy for the treatment of SLE compared with placebo.
Highlights
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, characterized by autoantibody production, complement activation, and immune complex deposition.[1]
Search strategy: The databases searched for this study included PubMed, EMBASE and Cochrane Library, before 4th September 2018, using atacicept, belimumab, blisibimod, epratuzumab, rituximab or tabalumab and SLE
The study analyzed six biologic agents for SLE in 21 randomized controlled trials. These results showed that the belimumab had the highest probability of being the best treatment compared with other biologic agents, according to network meta-analysis by network diagram makes it more intuitive
Summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, characterized by autoantibody production, complement activation, and immune complex deposition.[1] Auto-antibodies mediate inflammation and various organs damaged through immune complex formation.[2] We already knew that many factors such as infection environment, immunity and many other factor are closely related to cause this disease that adaptive immune system has been the focus of many studies.[3] Current treatment strategies rely heavily. This in turn leads to a cascade of events including increase in infections and malignancies, limit in immunosuppressives, long standing over reliance on corticosteroid therapy.[4] Currently available treatment has involved the use of anti-inflammatory or immunosuppressive non-steroidal anti-inflammatory drugs to deal with different situation.[5] This conventional treatment can be associated with organ damage and not completely effective in many patients, which highlighting a huge need in the area of SLE therapeutics.[6]. This study may improve a useful guide for selection of medication treatments for SLE
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
